PIM1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion
Distinguishing key factors that drive the switch from indolent to invasive disease will make a significant impact on guiding the treatment of prostate cancer (PCa) patients. Here, we identify a novel signaling pathway linking hypoxia and PIM1 kinase to the actin cytoskeleton and cell motility. An un...
Saved in:
Published in: | The Journal of cell biology Vol. 222; no. 6; p. 1 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Rockefeller University Press
05-06-2023
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Distinguishing key factors that drive the switch from indolent to invasive disease will make a significant impact on guiding the treatment of prostate cancer (PCa) patients. Here, we identify a novel signaling pathway linking hypoxia and PIM1 kinase to the actin cytoskeleton and cell motility. An unbiased proteomic screen identified Abl-interactor 2 (ABI2), an integral member of the wave regulatory complex (WRC), as a PIM1 substrate. Phosphorylation of ABI2 at Ser183 by PIM1 increased ABI2 protein levels and enhanced WRC formation, resulting in increased protrusive activity and cell motility. Cell protrusion induced by hypoxia and/or PIM1 was dependent on ABI2. In vivo smooth muscle invasion assays showed that overexpression of PIM1 significantly increased the depth of tumor cell invasion, and treatment with PIM inhibitors significantly reduced intramuscular PCa invasion. This research uncovers a HIF-1-independent signaling axis that is critical for hypoxia-induced invasion and establishes a novel role for PIM1 as a key regulator of the actin cytoskeleton. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. G. Mouneimne reported personal fees from MeCo Diagnostics outside the submitted work. No other disclosures were reported. |
ISSN: | 0021-9525 1540-8140 |
DOI: | 10.1083/jcb.202208136 |